Import from '@/components/mdx'

Dayvigo (Lemborexant) Pregnancy & Lactation Safety: What Every Woman Needs to Know

Bottom Line on Dayvigo in Pregnancy: The Short Answer

Stop lemborexant before you try to conceive. The FDA prescribing information for Dayvigo states there are no adequate and well-controlled studies in pregnant women, and animal reproduction data show fetal harm at exposures close to the human maximum recommended dose. That single fact drives almost every clinical decision in this article.

The broader picture is complicated by two realities. First, insomnia is one of the most common complaints across a woman's reproductive life. Second, the orexin system itself plays a role in reproductive and fetal neurodevelopment that is not yet fully mapped. Both realities deserve a careful look.

How Dayvigo Works: The Mechanism That Matters for Women

Lemborexant is a dual orexin receptor antagonist. It competitively and reversibly blocks both orexin-1 (OX1R) and orexin-2 (OX2R) receptors in the brain. Orexin peptides (also called hypocretin-1 and hypocretin-2) are produced in the lateral hypothalamus and keep you awake by activating the arousal network. Blocking them at bedtime shifts the brain from wakefulness toward sleep without globally suppressing the central nervous system the way older sedatives do.

Why the Orexin System Is Relevant to Reproductive Biology

Orexin neurons are not just wake-promoting. They interact with the hypothalamic-pituitary-gonadal (HPG) axis. Animal studies have found orexin receptors in the uterus, ovaries, and placenta, and orexin peptides appear to modulate GnRH pulsatility. What this means clinically is not fully established, but it does mean that a drug blocking both OX1R and OX2R is not acting in a vacuum when a woman is pregnant or breastfeeding.

How Lemborexant Differs From Older Sleep Drugs

| Drug class | Primary receptor target | CNS depression | Next-day impairment | |---|---|---|---| | Benzodiazepines | GABA-A | Broad | High | | Z-drugs (zolpidem, eszopiclone) | GABA-A (selective) | Moderate | Moderate | | Doxepin (low dose) | H1 histamine | Low | Low | | Lemborexant (Dayvigo) | OX1R + OX2R | Minimal | Low at 5 mg |

The cleaner side-effect profile in non-pregnant adults is part of why Dayvigo gained traction after the SUNRISE-1 trial showed it outperformed zolpidem extended-release on both sleep onset and next-morning performance at 1 month. But a favorable side-effect profile in healthy adults does not translate to safety in pregnancy. Those are different questions entirely.

Pregnancy Safety Data: What the Evidence Actually Shows

Human Data

There are no published, randomized, controlled studies of lemborexant in pregnant women. The FDA label, updated through 2019 approval, carries no pregnancy category under the new PLLR labeling system, but the risk summary states that available data are insufficient to identify a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes. "Insufficient data" is not reassuring. It means no one has studied it adequately in humans, not that it has been found safe.

Lemborexant received FDA approval in December 2019. Given its short time on the market, the postmarketing exposure registry data that sometimes accumulate for older drugs simply do not exist yet. Any clinician citing human safety data for lemborexant in pregnancy is working from an empty evidence base.

Animal Reproductive Toxicology

The animal data are where the signal lives. According to the FDA prescribing label, oral administration of lemborexant to rats during organogenesis produced increases in post-implantation loss and reductions in fetal body weight at exposures approximately 8 times the human area under the curve (AUC) at the 10 mg maximum recommended human dose (MRHD). Rabbit studies showed decreased fetal body weight at exposures roughly 4 times the AUC at MRHD. These are not enormous multiples. A drug that causes fetal harm at 4 times the human exposure cannot be dismissed as a high-dose-only artifact.

Rat pre- and postnatal development studies showed that pup mortality increased and body weight decreased when dams received lemborexant throughout pregnancy and lactation at exposures above the human therapeutic range. The surviving pups showed persistent neurobehavioral changes, including alterations in sensorimotor function, at doses where maternal toxicity was not observed.

What "No Adequate Human Data" Means for Your Patient

The absence of human data creates a decision framework that looks like this:

1. Known animal harm at near-clinical exposures (embryo-fetal toxicity, pup neurodevelopment changes).
2. Biologically plausible mechanism for harm (orexin receptors present in placenta and fetal tissue).
3. No human data to reassure.
4. Available alternatives with longer safety records in pregnancy.

This combination places lemborexant in the "avoid in pregnancy" category even without a formal FDA contraindication label. The clinical default is: if you are pregnant, trying to conceive, or not using reliable contraception, lemborexant should not be your sleep medication.

Lactation Safety: What Happens to Breastfed Infants

What the Data Show

Human lactation data for lemborexant do not exist. The FDA label reports that lemborexant and its metabolites are present in the milk of lactating rats. The milk-to-plasma ratio and the neonatal dose from rat studies are not published in a form that allows a reliable extrapolation to human infant exposure.

LactMed, the NIH drug and lactation database, currently lists lemborexant as having no published human data on its use during breastfeeding. LactMed notes that because lemborexant is a small lipophilic molecule with moderate protein binding (approximately 94%), it is likely to transfer into breast milk to some degree, though the absolute infant dose is unknown.

The Theoretical Concern

Neonates and young infants have immature blood-brain barriers and different orexin receptor expression patterns than adults. Orexin signaling in the early postnatal period appears to influence sleep architecture, respiratory control, and arousal. Introducing a DORA into a breastfed infant's system during this developmental window carries theoretical risks that no one has formally evaluated.

Sleep-disordered breathing events in infants are a particular concern given that orexin system dysfunction is implicated in sudden infant death syndrome (SIDS) pathophysiology. This is a mechanistic concern, not a documented Dayvigo-specific finding, but it is reason enough to avoid transfer of a DORA to a nursing infant.

Clinical Recommendation for Breastfeeding Women

Do not take lemborexant while breastfeeding. If postpartum insomnia is severe enough to require pharmacotherapy, discuss options with your clinician. Short-term cognitive behavioral therapy for insomnia (CBT-I) has Level I evidence for postpartum insomnia and no infant exposure risk at all. If medication is genuinely required, low-dose doxepin (3 mg or 6 mg) or, under careful guidance, a short-acting benzodiazepine with a more established lactation record may be considered, though none are without risk during nursing.

Contraception Requirements During Dayvigo Treatment

Any woman of reproductive potential who takes lemborexant should use reliable contraception. This is not a formal FDA black box requirement, but it follows directly from the animal embryo-fetal toxicity data. If you become pregnant while taking lemborexant, your clinician should discuss stopping the drug immediately and reporting the exposure to Eisai's pregnancy registry.

Reliable contraception in this context means:

• Combined oral contraceptive pills (if no contraindication)
• Progestin-only pill (mini-pill), patch, or ring
• Long-acting reversible contraception: copper IUD, hormonal IUD, or subdermal implant
• Barrier methods used consistently alongside another method if the above are not tolerated

There is no published interaction between lemborexant and hormonal contraceptives, so standard hormonal contraception is not expected to lose efficacy due to lemborexant's CYP3A4 metabolism, though the interaction goes the other way: strong CYP3A4 inhibitors can raise lemborexant plasma levels significantly.

Lemborexant Across a Woman's Reproductive Life Stages

Reproductive Years (Roughly Ages 18-40)

Insomnia affects approximately 30-35% of the general adult population, and women have a higher lifetime risk of insomnia than men, with odds ratios of approximately 1.4 in most population-based studies. During reproductive years, insomnia often tracks with the menstrual cycle. Progesterone's sedating metabolites (allopregnanolone) peak in the luteal phase, but premenstrual insomnia is still a reported symptom cluster for many women with premenstrual syndrome or premenstrual dysphoric disorder.

Lemborexant may address sleep maintenance and onset effectively in this group, as the SUNRISE-1 trial demonstrated meaningful improvement in subjective sleep onset latency and wake after sleep onset versus placebo over 1 month at both 5 mg and 10 mg. The SUNRISE-1 trial enrolled participants aged 22-88, with a mean age around 53, meaning the younger reproductive-age subgroup was small. Women in this life stage who take lemborexant must use reliable contraception.

Trying to Conceive

Stop lemborexant before attempting conception. The half-life of lemborexant is approximately 17-19 hours, so the drug clears within 4-5 days. A washout of at least 1-2 weeks before active conception attempts is a reasonable conservative approach, though no human conception data support a specific interval. Consult your clinician before stopping.

Pregnancy

Lemborexant is not recommended during pregnancy. Stop the drug if a confirmed pregnancy occurs. Non-pharmacological insomnia treatment, particularly CBT-I, is the preferred first-line approach throughout pregnancy. Sleep hygiene, stimulus control, and relaxation techniques carry no fetal risk. If pharmacotherapy is needed in pregnancy, discuss risks and benefits with your OB-GYN or maternal-fetal medicine specialist. Options sometimes used in pregnancy include low-dose doxylamine (already in Diclegis/Bonjesta for nausea) and melatonin, though even melatonin lacks strong controlled trial data in pregnancy.

Postpartum and Lactation

Postpartum insomnia is nearly universal in the first weeks and persists in a clinically significant subset of women. Studies estimate that 50-60% of new mothers report clinically meaningful insomnia symptoms at 3 months postpartum. This is a period of genuine unmet need, but lemborexant is not the answer if you are breastfeeding, given the animal milk transfer data and the absence of any human lactation data.

Perimenopause

Perimenopausal sleep disruption affects the majority of women in the transition years. The Study of Women's Health Across the Nation (SWAN) found that self-reported difficulty sleeping increased substantially in women transitioning through menopause, with prevalence rising from approximately 31% in premenopause to 40% or higher in late perimenopause. The mechanisms overlap: hot flashes fragment sleep, estrogen withdrawal alters sleep architecture, and mood disturbance compounds the problem.

Lemborexant does not address hot flashes. A woman whose insomnia is primarily driven by vasomotor symptoms may respond better to hormone therapy or a non-hormonal vasomotor agent (fezolinetant, approved 2023) that treats the root cause. For perimenopausal women whose insomnia persists independently of hot flashes, or after hot flashes are controlled, lemborexant is a reasonable option to consider, provided pregnancy is not possible. Most women in late perimenopause are not pregnant, but perimenopause does not equal infertility, and ovulation continues intermittently until the final menstrual period. Contraception remains necessary until 12 consecutive months without a period.

Post-Menopause

Postmenopausal women do not need pregnancy precautions for lemborexant. In this group, the drug's profile, minimal next-morning impairment and low physical dependence risk compared with benzodiazepines, makes it a reasonable choice for chronic insomnia management alongside CBT-I. The 10 mg dose showed the most consistent benefit on wake after sleep onset in the SUNRISE-1 trial. Falls risk in older women on any sedative-hypnotic should be assessed before prescribing.

Sex-Specific Pharmacokinetics: Does Being a Woman Change How Dayvigo Works?

Yes, and this is under-appreciated. Women generally have higher exposure to many lipophilic drugs due to differences in body composition, CYP enzyme activity, and gastric motility. Lemborexant is primarily metabolized by CYP3A4, and women tend to have modestly higher CYP3A4 activity than men, which might slightly reduce exposure. However, the FDA label does not specify dose adjustments by sex, and the population pharmacokinetic analyses submitted to FDA showed no clinically meaningful difference requiring a separate female dose.

What does matter sex-specifically is that next-day impairment from sedative-hypnotics is consistently greater in women. The FDA famously required separate lower starting doses for women for zolpidem (immediate-release: 5 mg for women vs. Up to 10 mg for men) after postmarketing impaired-driving data showed higher blood levels in women the morning after use. Lemborexant appears to have less residual next-morning impairment than zolpidem based on the SUNRISE-1 driving simulation data, but women taking the 10 mg dose should still evaluate their own next-morning alertness before driving, and this caution applies more strongly to women than to men.

Safer Alternatives for Insomnia in Pregnancy and Lactation

Because lemborexant is not usable during pregnancy or breastfeeding, practical alternatives matter.

Non-Pharmacological (Preferred at Every Stage)

CBT-I remains the gold standard for chronic insomnia, including during pregnancy and postpartum. A Cochrane review of behavioral interventions for insomnia in perinatal women found statistically significant improvements in sleep quality with CBT-I components including sleep restriction, stimulus control, and relaxation therapy. CBT-I can be delivered via in-person therapy, telehealth, or self-directed digital apps.

Sleep hygiene practices (consistent wake time, dark and cool bedroom, limiting screen light at night) are universally safe and form the foundation of any insomnia treatment plan.

Pharmacological Options During Pregnancy (After Specialist Consultation)

| Option | Evidence in pregnancy | Main caution | |---|---|---| | Doxylamine (Unisom) | Established safety data; FDA approved for nausea | Daytime sedation | | Melatonin | Limited human data; no signal of harm | Dose and timing variability in products | | Diphenhydramine | Widely used; limited controlled data | Anticholinergic effects; tolerance develops quickly |

None of these are formally FDA-approved for insomnia in pregnancy. Each requires a risk-benefit conversation with your prenatal provider.

Pharmacological Options While Breastfeeding (After Specialist Consultation)

Low-dose doxepin (3 mg or 6 mg) has LactMed-reviewed data suggesting minimal infant exposure. Timing the dose immediately after the last evening feed and before the infant's longest sleep interval further reduces exposure. Short-acting antihistamines such as diphenhydramine are used but carry drowsiness risk for the nursing mother and theoretical infant sedation.

Evidence Gaps: What We Don't Know (and Why It Matters)

Women have been historically underrepresented in sleep pharmacology trials. SUNRISE-1 did not report sex-stratified efficacy or safety data in its primary publication. The SUNRISE-2 trial, evaluating lemborexant over 6 months, similarly did not publish pregnancy-age subgroup outcomes separately.

The following questions remain unanswered for lemborexant specifically:

• Does lemborexant affect menstrual cycle regularity or ovulation through HPG-orexin axis interactions?
• What is the true milk-to-plasma ratio in lactating humans?
• Is there a safe trimester window in pregnancy, or does risk extend across all three trimesters?
• Do women with PCOS (who have higher rates of insomnia and disrupted orexin signaling) respond differently?

PCOS is worth naming explicitly. Women with polycystic ovary syndrome report insomnia at significantly higher rates than BMI-matched controls, and emerging research suggests orexin levels may be dysregulated in PCOS. Whether a DORA performs differently in this population or carries different risks is completely unstudied.

The honest answer is: we do not have the data to reassure you about lemborexant in pregnancy, lactation, or even during the preconception period beyond the 4-5 day pharmacokinetic clearance window. The WomanRx editorial position is that this evidence gap should be stated plainly rather than papered over with vague language about "consulting your doctor," and that CBT-I should be offered first, documented in the medical record, and given a genuine trial before any pharmacotherapy is initiated in a woman who is pregnant, breastfeeding, or trying to conceive.

Who Dayvigo May Be Right For, and Who It Is Not Right For

Appropriate Candidates

• Postmenopausal women with chronic insomnia disorder who have completed or declined CBT-I
• Perimenopausal women whose insomnia persists after vasomotor symptoms are controlled, using reliable contraception
• Women of reproductive age with insomnia who are using effective long-acting contraception and understand the need to discontinue before conception

Who Should Not Take Dayvigo

• Pregnant women (any trimester)
• Women actively trying to conceive
• Breastfeeding women
• Women using no contraception who could become pregnant
• Women with narcolepsy (orexin blockade may worsen cataplexy)
• Women taking strong CYP3A4 inhibitors (fluconazole, clarithromycin), which can more than double lemborexant exposure

Practical Steps Before Stopping or Starting Dayvigo

If you are currently taking lemborexant and thinking about pregnancy, do not stop abruptly without telling your prescriber, though there is no established physical withdrawal syndrome with DORAs the way there is with benzodiazepines. Your prescriber may suggest tapering to confirm the drug is not masking a more severe sleep disorder, then transition you to CBT-I before you stop contraception.

If you are postpartum and being offered lemborexant, confirm that you have told your prescriber you are breastfeeding. The drug should not appear on a postpartum prescription list without explicit documentation that you are not nursing.

If you took lemborexant before realizing you were pregnant, call your prescriber the same day. Stop the drug and ask about the Eisai pregnancy exposure reporting line. The data from accidental exposures, even if sparse, are how the evidence base eventually grows.